4 results
Approved WMOCompleted
To assess sorafenib pharmacokinetics and biodistribution, K-Ras mutational status, tumor uptake and tumor response in NSCLC patients.
Approved WMOCompleted
The purpose of this study is to ascertain the efficacy, safety, tolerability and pharmacokineticsof LNP023 over a 24-week treatment period compared with rituximab in subjects with MN.
Approved WMOCompleted
To examine the effects of mono- and combination therapy with linagliptin and empagliflozine on renal hemodynamics
Approved WMOCompleted
To evaluate the dose response relationship of LNP023 on the reduction in proteinuria versus placebo after 90 days of treatment in patients with IgA nephropathy.